医疗诊断公司Bluejay Diagnostics Inc（股票代码：BJDX）宣布取得两项关键进展：其Symon™ II临床研究已完成545名患者入组目标，同时公司将产品制造准备期规划延长至2026年。
在临床研究方面，Symon™ II研究旨在评估该公司专利技术平台的应用效能。此次顺利完成患者招募，为后续数据收集和分析工作奠定坚实基础。研究团队将按计划推进后续临床验证流程。
与此同时，公司决定将制造体系准备期延长至2026年。这一战略调整使Bluejay Diagnostics能够更充分地完善生产质量控制体系，确保未来产品商业化过程中的供应链稳定性。该举措也反映出公司对长期市场布局的审慎考量。
这两项进展标志着Bluejay Diagnostics在技术创新与产业化落地之间实现了协同推进。临床研究的顺利开展为产品获批提供数据支撑，而制造准备期的延长则体现了公司对产品质量管控的严谨态度。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.